BackBeat® Cardiac Neuromodulation Therapy (CNT) for Immediate, Substantial and Sustained Lowering of Blood Pressure

Daniel Burkhoff MD PhD
Director Heart Failure, Hemodynamics and Mechanical Support Research
Cardiovascular Research Foundation
I, Daniel Burkhoff, MD PHD have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest in the context of the subject of this presentation.

**Disclosure Statement of Financial Interest**

<table>
<thead>
<tr>
<th>AFFILIATION/FINANCIAL RELATIONSHIP</th>
<th>COMPANY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Consultant</td>
<td>BackBeat Medical/Orchestra BioMed, Inc</td>
</tr>
</tbody>
</table>
BackBeat® Cardiac Neuromodulation Therapy (CNT) Overview

- Bioelectronic therapy that immediately, substantially and chronically lowers blood pressure (BP) while simultaneously modulating Autonomic Nervous System (ANS)
  - Mimics effects of multiple medications by reducing preload, afterload and sympathetic tone
- Can be delivered using standard rhythm management device hardware (such as dual chamber pacemakers)
- Applicable to wide range of hypertensive patients including Isolated Systolic Hypertension
  - Hypertensive patients who are also indicated for a pacemaker
    - Over 70% of pacemaker patients have hypertension
  - Uncontrolled hypertensive patients
BackBeat® CNT Clinical Benefits

- Programmable: Blood Pressure reduction is adjustable
- Immediate response
- Substantial reduction in Blood Pressure
- Sustained effect
- High responder rate
- Broad applicability
  - All subgroups including ISH
  - Wide range of initial blood pressure
  - Pacemaker and non-pacemaker population
BackBeat® CNT is Programmable and Adjustable

Reduction in Blood Pressure Can be Titrated by Modifying Therapy Parameters as Needed

- Acute clinical study (N=18) treated with 4 different sets of BackBeat® CNT parameters demonstrates control of the reduction in blood pressure

<table>
<thead>
<tr>
<th>Changes in Systolic Blood Pressure</th>
<th>Set 1</th>
<th>Set 2</th>
<th>Set 3</th>
<th>Set 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Change in Systolic BP (mmHg)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>-25</td>
<td>-20</td>
<td>-15</td>
<td>-10</td>
</tr>
<tr>
<td></td>
<td>-12.5</td>
<td>-10</td>
<td>-9</td>
<td>-8</td>
</tr>
<tr>
<td></td>
<td>-8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>-7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>-6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>-5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>-4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>-3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>-2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* P< 0.01
BackBeat® CNT MODERATO I Study Design

- Patients with **Persistent Hypertension** (office BP > 150mmHg) despite 2 or more anti-hypertensive medications and an indication for a Pacemaker
- One-month pacemaker only run-in phase
- Primary safety and efficacy evaluation at 3 months post BackBeat® CNT activation; follow-up to 2 years

![Flowchart Diagram]

1. **Informed Consent**
2. **Screening & Baseline**
   - BP criteria? Avg > 150 mmHg
     - YES
       - Pacemaker Treatment Phase
         - N=35
         - One month with pacing only
         - Moderate system Implant
         - YES
           - Activate BackBeat® CNT Therapy
             - N=27
             - 3 Months Follow Up
             - NO
               - Optional Activation of CNT Therapy
                 - N=8
                 - 3 Months Follow up
                 - NO
                   - Withdraw from Study
3. **Withdraw from Study**
Immediate & Substantial Reduction in BP

Ambulatory Blood Pressure Decreased Significantly Immediately After Activation and Remained Lowered by 14.2 mmHg After 3 Months of Therapy

The Effect of BackBeat® CNT on Ambulatory Blood Pressure

Immediate and Substantial Effect of BackBeat® CNT on Ambulatory Blood Pressure
BP Reduction Sustained Through 2 Years

BackBeat® CNT Maintains Significant Reduction in Office Systolic BP over 2 years

The Effect of BackBeat® CNT on Office Systolic Blood Pressure

-23.4±20.5 mmHg

* P < 0.0001

Systolic blood pressure (mmHg)

Time from activation (months)

Run-In Activation

0 1 2 3 6 12 18 24

130 140 150 160 170
High Responder Rate in Challenging Patient Population

- Baseline AMB systolic pressure: 137 mmHg
- Average reduction of 14.2 mmHg
- 78% of patients had Isolated Systolic Hypertension (ISH)
- Responder Rate:
  - 85% SBP reduced > 5mmHg
  - 74% SBP reduced > 10mmHg

3-month change in ambulatory blood pressure (mmHg)

BackBeat® CNT Therapy

BP Increase n=2 (7%)
BP Decrease n=25 (93%)

* Patient 76 YO on 5 HTN drugs, non responder to RDN therapy (baseline office BP 168/80); After re-optimization of stimulation parameters 24H AMB BP reduced by 14.3 mmHg and office BP by 33/9 mmHg

* Petr Neuzil, et. al. Pacemaker-Mediated Programmable Hypertension Control Therapy. J Am Heart Assoc. 2017; Dec 23;6(12): e006974. DOI: 10.1161/JAHA.117.006974
BackBeat® CNT – 2 Year Safety Results

2 Year Safety Consistent with Expected Mechanism of Action

- Reduction in Heart Rate is indicative of reduced sympathetic activity
- Reduction in volumes with no change in EF suggests improvement of cardiac function

![Graphs showing changes in Heart Rate, Ejection Fraction, End Systolic Volume, and End Diastolic Volume over 24 months compared to pre-act.](image-url)

*P<0.05
MODERATO II: Randomized, Controlled Study

- Prospective, 1:1 randomized double-blind active treatment (BackBeat® CNT) versus standard medical therapy
- Patient population: Uncontrolled blood pressure (office Systolic > 140, Day AMB BP > 130 mmHg) treated with at least one anti-hypertension medication that are indicated for a dual chamber pacemaker
  - Primary Effectiveness Endpoint: Mean reduction in 24 hour systolic ambulatory blood pressure following 6 months of therapy
  - Primary Safety Endpoint: rate of MACE at 6 month between the treatment and control

- Cohort I: European initial cohort (~50 patients) – results expected Q2 2019
- Cohort II: Global, multicenter cohort (170 patients) – enrollment starts in Q4 2018
BackBeat® CNT Program Update

BackBeat® CNT enables immediate, substantial and sustained lowering of blood pressure

• 2-year data from European MODERATO I study demonstrates significant and sustained efficacy of BackBeat® CNT

• Study met the safety endpoint. In addition, the safety data suggests improvement in cardiac function

• BackBeat CNT and Moderato IPG submitted for CE mark

• Randomized, double-blind MODERATO II study to further substantiate benefit of therapy:
  • Cohort I: European initial cohort (~50 patients) – results expected Q2 2019
  • Cohort II: Global, multicenter cohort (170 patients) – enrollment starts in Q4 2018
THANK YOU!